Literature DB >> 16905334

Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.

Scott K Ziolko1, Lisa A Weissfeld, William E Klunk, Chester A Mathis, Jessica A Hoge, Brian J Lopresti, Steven T DeKosky, Julie C Price.   

Abstract

Deposition of amyloid plaques is believed to be a central event in the development of Alzheimer's disease (AD). The present study was undertaken to evaluate statistical methods for the assessment of group differences in retention of an amyloid imaging agent, PIB, throughout the brain and to compare these results to FDG studies of glucose metabolism performed in the same subjects on the same day. PET studies were performed in 10 mild to moderate AD and 11 control subjects. Parametric images of PIB retention (over 90 min post-injection) were generated using the Logan graphical analysis with cerebellar (CER, reference region) data as input. FDG parametric images were created by summing the uptake over 40-60 min post-injection and normalizing that to the CER to give a standardized uptake value ratio. Data were compared using parametric (SPM) and non-parametric (SnPM) statistical methods with familywise error (FWE) and false discovery rate (FDR) corrections. PIB results were consistent with previous regional results as AD subjects showed highly significant retention in frontal, parietal, temporal, and posterior cingulate cortices (FDR-corrected p<1.4e-10). FDG results showed regions of marginally significant decreases in uptake in AD subjects (frontal, parietal, temporal, posterior cingulate cortices: FDR-corrected p<0.1) consistent with previous studies. Relative to FDG, the PIB analyses were of greater statistical significance and larger spatial extent. Additionally, the PIB analyses retained significance after both FWE and FDR corrections. These results indicate that voxel-based methods will be useful for future larger longitudinal studies of amyloid deposition that could improve AD diagnosis and anti-amyloid therapy assessment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905334     DOI: 10.1016/j.neuroimage.2006.05.063

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  45 in total

1.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.

Authors:  Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

2.  Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.

Authors:  D P Devanand; Arthur Mikhno; Gregory H Pelton; Katrina Cuasay; Gnanavalli Pradhaban; J S Dileep Kumar; Neil Upton; Robert Lai; Roger N Gunn; V Libri; Xinhua Liu; Ronald van Heertum; J John Mann; Ramin V Parsey
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-04-29       Impact factor: 2.680

3.  A shift in the paradigm of treatment.

Authors:  Edmund G Howe
Journal:  Psychiatry (Edgmont)       Date:  2006-11

4.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

5.  Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data.

Authors:  Sargo Aalto; Noora M Scheinin; Nina M Kemppainen; Kjell Någren; Marita Kailajärvi; Mika Leinonen; Mika Scheinin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

6.  Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.

Authors:  Timo Grimmer; Matthias Riemenschneider; Hans Förstl; Gjermund Henriksen; William E Klunk; Chester A Mathis; Tohru Shiga; Hans-Jürgen Wester; Alexander Kurz; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2009-03-06       Impact factor: 13.382

Review 7.  Amyloid-β positron emission tomography imaging probes: a critical review.

Authors:  Vladimir Kepe; Mateen C Moghbel; Bengt Långström; Habib Zaidi; Harry V Vinters; Sung-Cheng Huang; Nagichettiar Satyamurthy; Doris Doudet; Eyal Mishani; Robert M Cohen; Poul F Høilund-Carlsen; Abass Alavi; Jorge R Barrio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 8.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

9.  Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users.

Authors:  Daniel S Albrecht; Patrick D Skosnik; Jennifer M Vollmer; Margaret S Brumbaugh; Kevin M Perry; Bruce H Mock; Qi-Huang Zheng; Lauren A Federici; Elizabeth A Patton; Christine M Herring; Karmen K Yoder
Journal:  Drug Alcohol Depend       Date:  2012-08-19       Impact factor: 4.492

10.  Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.

Authors:  Ann D Cohen; Julie C Price; Lisa A Weissfeld; Jeffrey James; Bedda L Rosario; Wenzhu Bi; Robert D Nebes; Judith A Saxton; Beth E Snitz; Howard A Aizenstein; David A Wolk; Steven T Dekosky; Chester A Mathis; William E Klunk
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.